The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist
(GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians
face numerous practical questions that cannot be answered by recently published trial
results, current guidelines and summaries of product characteristics. In April 2019,
a scientific meeting was held with the participation of nine experts from four Central
and Eastern European countries to provide expert consensus on the optimal daily use
of the insulin glargine and lixisenatide FRC (iGlarLixi). Topics included the positioning
and initiation of iGlarLixi and the management of treatment. This paper summarizes
the outcomes of the meeting.
